Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroo Ishida

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
BMJ Case Reports|September 10, 2015
Crizotinib-induced pancreatic pseudocyst: a novel adverse eventHiroo Ishida, Wataru Ichikawa, Yasutsuna Sasaki
World Journal of Gastroenterology|November 26, 2015
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerKen-ichi Fujita, Yutaro Kubota, Hiroo Ishida, et al.
Current Drug Metabolism|January 7, 2017
Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical PharmacologyKen-Ichi Fujita, Hiroo Ishida, Yutaro Kubota, et al.
Cancers|July 2, 2020
Single-Drug Approach with Edoxaban is Effective for Resolving Non-Acute Cancer-Associated Venous Thrombosis: A Single-Arm Retrospective AnalysisHirokazu Toshima, Atsushi Hisamatsu, Kouji Kobayashi, et al.
International Journal of Clinical Pharmacy|November 20, 2024
Cost-effectiveness analysis of first line pembrolizumab monotherapy for high programmed cell death ligand 1 expressed, advanced non-small cell lung cancer in JapanKazuki Tomura, Hiroyuki Sakamaki, Shuichi Nawata, et al.
In Vivo (Athens, Greece)|October 31, 2019
VEGF Inhibitors Do Not Increase D-dimer Levels in Colorectal Cancer Patients Without Venous Thromboembolism: A Retrospective Non-inferiority AnalysisHirokazu Toshima, Toshikazu Ikusue, Atsushi Hisamatsu, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2024
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancerKoutaro Ono, Remi Murase, Natsumi Matsumoto, et al.
Cancer Chemotherapy and Pharmacology|November 24, 2025
Association of IL12RB2, RORC, and class II HLA polymorphisms with severe erythema multiforme of regorafenib in Japanese patients with colorectal cancerGeonwoo Lee, Remi Murase, Natsumi Matsumoto, et al.
Clinical and Translational Science|July 10, 2023
Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancerKen-Ichi Fujita, Natsumi Matsumoto, Remi Murase, et al.
Cancer Science|August 14, 2015
Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?Yasutsuna Sasaki, Kazuyuki Hamada, Toshikado Kaneta, et al.
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
BMJ Case Reports|September 10, 2015
Crizotinib-induced pancreatic pseudocyst: a novel adverse eventHiroo Ishida, Wataru Ichikawa, Yasutsuna Sasaki
World Journal of Gastroenterology|November 26, 2015
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerKen-ichi Fujita, Yutaro Kubota, Hiroo Ishida, et al.
Current Drug Metabolism|January 7, 2017
Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical PharmacologyKen-Ichi Fujita, Hiroo Ishida, Yutaro Kubota, et al.
Cancers|July 2, 2020
Single-Drug Approach with Edoxaban is Effective for Resolving Non-Acute Cancer-Associated Venous Thrombosis: A Single-Arm Retrospective AnalysisHirokazu Toshima, Atsushi Hisamatsu, Kouji Kobayashi, et al.
International Journal of Clinical Pharmacy|November 20, 2024
Cost-effectiveness analysis of first line pembrolizumab monotherapy for high programmed cell death ligand 1 expressed, advanced non-small cell lung cancer in JapanKazuki Tomura, Hiroyuki Sakamaki, Shuichi Nawata, et al.
In Vivo (Athens, Greece)|October 31, 2019
VEGF Inhibitors Do Not Increase D-dimer Levels in Colorectal Cancer Patients Without Venous Thromboembolism: A Retrospective Non-inferiority AnalysisHirokazu Toshima, Toshikazu Ikusue, Atsushi Hisamatsu, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2024
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancerKoutaro Ono, Remi Murase, Natsumi Matsumoto, et al.
Cancer Chemotherapy and Pharmacology|November 24, 2025
Association of IL12RB2, RORC, and class II HLA polymorphisms with severe erythema multiforme of regorafenib in Japanese patients with colorectal cancerGeonwoo Lee, Remi Murase, Natsumi Matsumoto, et al.
Clinical and Translational Science|July 10, 2023
Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancerKen-Ichi Fujita, Natsumi Matsumoto, Remi Murase, et al.
Cancer Science|August 14, 2015
Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?Yasutsuna Sasaki, Kazuyuki Hamada, Toshikado Kaneta, et al.
Pageof 8